Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €269.09 EUR
Change Today +3.02 / 1.14%
Volume 410.0
IDP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 617-679-2000

Fax:

is managing various Phase 3 studies of GAZYVA. GOYA: Investigating the efficacy and safety of GAZYVA in combination with CHOP chemotherapy compared to RITUXAN with CHOP chemotherapy in previously untreated patients with CD20-positive diffuse large B-cell lymphoma. GALLIUM: Investigating the efficacy and safety of GAZYVA in combination with chemotherapy followed by maintenance with GAZYVA compared to RITUXAN in combination with chemotherapy followed by maintenance with RITUXAN in previously untreated patients with indolent non-Hodgkin's lymphoma. GADOLIN: Investigating the efficacy and safety of GAZYVA plus bendamustine compared with bendamustine alone in patients with RITUXAN-refractory, indolent non-Hodgkin's lymphoma. In 2015, the Roche Group announced positive results from the Phase 3 GADOLIN study. In 2014, Isis Pharmaceuticals, Inc. (Isis) announced the initiation of a pivotal Phase 3 study evaluating ISIS-SMN in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. This Phase 3 study, known as ENDEAR, is a randomized, double-blind, sham-procedure controlled 13 month study in approximately 110 infants diagnosed with SMA. Business Relationships The company has a collaboration agreement with AbbVie Biotherapeutics, Inc. targeted at advancing the development and commercialization of ZINBRYTA (daclizumab high yield process) in MS. The company collaborates with Acorda to develop and commercialize products containing fampridine in markets outside the U.S. In 2014, the company entered into a collaboration with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize E2609 and BAN2401, two Eisai product candidates for the treatment of Alzheimer’s disease. The agreement also provides Eisai with options to jointly develop and commercialize two of its candidates for Alzheimer’s disease, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody, upon the exchange of clinical data. The company has three separate exclusive, worldwide option and collaboration agreements with Isis under, which both companies would develop and commercialize antisense therapeutics for up to three gene targets, Isis’ product candidates for the treatment of myotonic dystrophy type 1, and the antisense investigational candidate, ISIS-SMNRx for the treatment of SMA. The company has an agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics) that established an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. In 2013, pursuant to the company’s agreement with Samsung Biologics, it exercised its right to enter into an agreement with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe. Under the agreement, the company would be responsible for commercialization of these product candidates across Europe. In January 2015, Samsung Bioepis' MAA for its ENBREL (etanercept) biosimilar candidate, SB4, was validated and accepted for review by the EMA. In 2014, the company entered into an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. under which both companies would develop and commercialize product candidates using gene editing technologies for the treatment of two inherited blood disorders, sickle cell disease, and beta-thalassemia. Patents and Other Proprietary Rights The company’s trademarks are important to it and are generally covered by trademark applications or registrations in the U.S. Patent and Trademark Office and the patent or trademark offices of other countries. The company also uses trademarks licensed from third parties, such as the trademark FAMPYRA, which it licenses from Acorda. AVONEX and PLEGRIDY The company has the U.S. patents and patent applications, and various corresponding foreign counterparts, related to AVONEX and/or PLEGRIDY. Its U.S. patent no. 7,588,755 claims the use of recombinant beta interferon for immunomodulation or treating a viral condition, viral disease, cancers or tumors. This patent, which expires in September 2026, covers the treatment of MS with AVONEX and PLEG

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €269.09 EUR +3.02

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.02 USD +0.38
Astellas Pharma Inc ¥1,804 JPY +23.00
Celgene Corp $124.04 USD +1.00
Shire PLC 5,025 GBp +10.00
Thermo Fisher Scientific Inc $126.52 USD -1.39
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
Price/Earnings 20.6x
Price/Sales 7.0x
Price/Book 5.7x
Price/Cash Flow 18.4x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit www.biogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.